Quest Diagnostics Q2 Revenues Rise 4 Percent, Beat Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb) – Quest Diagnostics today reported a 4 percent increase year over year in its second quarter revenues, as the company narrowly beat consensus analyst estimates on the top and bottom lines.

Quest reported that for the three months ending June 30, it had $1.90 billion in revenues, up from $1.82 billion in the year-ago quarter. The average analyst estimate was for $1.88 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.